Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab

NCT00897754 | Completed

• 2 other identifiers: CDR0000560986ECOG-E3200T2
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment. PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.

Conditions

Colorectal Cancer

Keywords

adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent rectal cancer; stage III rectal cancer; stage IV rectal cancer; recurrent colon cancer; stage III colon cancer; stage IV colon cancer

Outcome Measures

Primary Outcomes (4)

• Mean scores for VEGFb and pan-VEGF gene expression by IHC

  1 month

• Gene expression as measured by tissue microarrays

  1 month

• Splice form expression as measured by reverse transcriptase-PCR

  1 month

• VEGF165b protein expression as measured by ELISA

  1 month

Interventions

gene expression analysis GENETIC

protein expression analysis GENETIC

reverse transcriptase-polymerase chain reaction GENETIC

immunoenzyme technique OTHER

immunohistochemistry staining method OTHER

immunologic technique OTHER

Eligibility Criteria

• Age: 18 Years - 120 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Samples submitted for research from patients participating in E3200

DISEASE CHARACTERISTICS: * Tumor tissue samples available from patients with advanced or metastatic adenocarcinoma of the colon or rectum * Receiving bevacizumab on clinical trial E-3200 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• ECOG-ACRIN Cancer Research Group: lead
• National Cancer Institute (NCI): collaborator

MeSH Terms

Conditions

Colorectal Neoplasms; Colonic Neoplasms; Rectal Neoplasms

Interventions

Gene Expression Profiling; Reverse Transcriptase Polymerase Chain Reaction; Immunoenzyme Techniques; Immunohistochemistry; Immunologic Techniques

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Genetic Techniques; Investigative Techniques; Polymerase Chain Reaction; Nucleic Acid Amplification Techniques; Immunoassay; Molecular Probe Techniques; Histocytochemistry; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Histological Techniques

Study Officials

• David Bates, PhD

  Bristol Heart Institute at University of Bristol

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2009
• First Posted: May 12, 2009
• Study Start: July 24, 2007
• Primary Completion: February 1, 2009
• Study Completion: February 1, 2009
• Last Updated: May 19, 2017

Record last verified: 2017-05